Istari Oncology, Inc. is a biotechnology firm pioneering novel immunotherapies for the treatment of solid tumor patients.
Istari has developed a passionate and experienced leadership team that is focused on clinical trial strategy and execution, as well as collaboration with the world’s major cancer centers and oncology biotech companies.
The company’s main asset is lerapolturev, an investigational immunotherapy based on the Sabin oral poliovirus vaccine.Lerapoluriv is a novel drug designed to eliminate neurotoxicity while optimizing multiple distinct mechanisms of action in order to stimulate a whole systemic antitumor response.
At Istari, they are pioneering a novel approach to immunotherapy that may give hope to patients battling cancer.
The connections between cancer patients, survivors, and their caregivers are personal and heartfelt. Istari is committed to improving the lives of others by combining a data-driven mentality with a goal to improve outcomes in favor of patients.
Their company mission motivates them to bring together people with interests and a passion for battling cancer.